Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Cash from Operations (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Cash from Operations for 13 consecutive years, with 19716000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 168.92% to 19716000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 138513000.0 through Dec 2025, down 577.66% year-over-year, with the annual reading at 138513000.0 for FY2025, 577.66% down from the prior year.
  • Cash from Operations hit 19716000.0 in Q4 2025 for Coherus Oncology, up from 46339000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 59734000.0 in Q2 2024 to a low of 99953000.0 in Q4 2022.
  • Historically, Cash from Operations has averaged 30619650.0 across 5 years, with a median of 42627000.0 in 2023.
  • Biggest five-year swings in Cash from Operations: plummeted 26515.43% in 2022 and later skyrocketed 321.13% in 2024.
  • Year by year, Cash from Operations stood at 52322000.0 in 2021, then plummeted by 91.03% to 99953000.0 in 2022, then soared by 87.06% to 12937000.0 in 2023, then surged by 321.13% to 28608000.0 in 2024, then crashed by 168.92% to 19716000.0 in 2025.
  • Business Quant data shows Cash from Operations for CHRS at 19716000.0 in Q4 2025, 46339000.0 in Q3 2025, and 46632000.0 in Q2 2025.